-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Multiple -X- _ B-Patient
sclerosis -X- _ I-Patient
( -X- _ I-Patient
MS -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
characterized -X- _ O
by -X- _ O
central -X- _ O
nervous -X- _ O
system -X- _ O
inflammation -X- _ O
and -X- _ O
demyelination -X- _ O
, -X- _ O
and -X- _ O
increasing -X- _ O
evidence -X- _ O
demonstrates -X- _ O
significant -X- _ O
neuronal -X- _ O
damage -X- _ O
also -X- _ O
occurs -X- _ O
and -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
permanent -X- _ O
functional -X- _ O
impairment. -X- _ O
Current -X- _ O
MS -X- _ O
therapies -X- _ O
have -X- _ O
limited -X- _ O
ability -X- _ O
to -X- _ O
prevent -X- _ O
neuronal -X- _ O
damage -X- _ O
, -X- _ O
suggesting -X- _ O
additional -X- _ O
neuroprotective -X- _ O
therapies -X- _ O
are -X- _ O
needed. -X- _ O
Compounds -X- _ O
that -X- _ O
activate -X- _ O
the -X- _ O
NAD -X- _ O
( -X- _ O
+ -X- _ O
) -X- _ O
-dependent -X- _ O
SIRT1 -X- _ O
deacetylase -X- _ O
prevent -X- _ O
neuronal -X- _ O
loss -X- _ O
in -X- _ O
an -X- _ O
autoimmune-mediated -X- _ O
MS -X- _ O
model -X- _ O
, -X- _ O
but -X- _ O
the -X- _ O
mechanism -X- _ O
of -X- _ O
this -X- _ O
effect -X- _ O
is -X- _ O
unknown -X- _ O
, -X- _ O
and -X- _ O
it -X- _ O
is -X- _ O
unclear -X- _ O
whether -X- _ O
SIRT1 -X- _ B-Intervention
activating -X- _ I-Intervention
compounds -X- _ I-Intervention
exert -X- _ O
similar -X- _ O
effects -X- _ O
in -X- _ O
demyelinating -X- _ O
disease -X- _ O
induced -X- _ O
by -X- _ O
other -X- _ O
etiologies. -X- _ O
We -X- _ O
measured -X- _ O
neuronal -X- _ O
loss -X- _ O
in -X- _ O
C57BL -X- _ B-Patient
/ -X- _ I-Patient
6 -X- _ I-Patient
mice -X- _ I-Patient
inoculated -X- _ I-Patient
with -X- _ I-Patient
a -X- _ I-Patient
neurotropic -X- _ I-Patient
strain -X- _ I-Patient
of -X- _ I-Patient
mouse -X- _ I-Patient
hepatitis -X- _ I-Patient
virus -X- _ I-Patient
, -X- _ I-Patient
MHV-A59 -X- _ I-Patient
, -X- _ O
that -X- _ O
induces -X- _ O
an -X- _ O
MS-like -X- _ O
disease. -X- _ O
RESULTS -X- _ O
: -X- _ O
Oral -X- _ B-Outcome
treatment -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
SIRT1 -X- _ I-Outcome
activating -X- _ I-Outcome
compound -X- _ I-Outcome
SRTAW04 -X- _ I-Outcome
significantly -X- _ I-Outcome
increased -X- _ I-Outcome
SIRT1 -X- _ I-Outcome
activity -X- _ I-Outcome
within -X- _ I-Outcome
optic -X- _ I-Outcome
nerves -X- _ I-Outcome
and -X- _ I-Outcome
prevented -X- _ I-Outcome
neuronal -X- _ I-Outcome
loss -X- _ I-Outcome
during -X- _ I-Outcome
optic -X- _ I-Outcome
neuritis -X- _ I-Outcome
, -X- _ I-Outcome
an -X- _ I-Outcome
inflammatory -X- _ I-Outcome
demyelinating -X- _ I-Outcome
optic -X- _ I-Outcome
nerve -X- _ I-Outcome
lesion -X- _ I-Outcome
that -X- _ I-Outcome
occurs -X- _ I-Outcome
in -X- _ I-Outcome
MS -X- _ I-Outcome
and -X- _ I-Outcome
its -X- _ I-Outcome
animal -X- _ I-Outcome
models. -X- _ I-Outcome
MHV-A59 -X- _ I-Outcome
induced -X- _ I-Outcome
neuronal -X- _ I-Outcome
loss -X- _ I-Outcome
was -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
reactive -X- _ I-Outcome
oxygen -X- _ I-Outcome
species -X- _ I-Outcome
( -X- _ I-Outcome
ROS -X- _ I-Outcome
) -X- _ I-Outcome
accumulation -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
SRTAW04 -X- _ I-Outcome
treatment -X- _ I-Outcome
significantly -X- _ I-Outcome
reduced -X- _ I-Outcome
ROS -X- _ I-Outcome
levels -X- _ I-Outcome
while -X- _ I-Outcome
promoting -X- _ I-Outcome
increased -X- _ I-Outcome
expression -X- _ I-Outcome
of -X- _ I-Outcome
enzymes -X- _ I-Outcome
involved -X- _ I-Outcome
in -X- _ I-Outcome
mitochondrial -X- _ I-Outcome
function -X- _ I-Outcome
and -X- _ I-Outcome
reduction -X- _ I-Outcome
of -X- _ I-Outcome
ROS. -X- _ I-Outcome
SRTAW04 -X- _ I-Outcome
exerted -X- _ I-Outcome
similar -X- _ I-Outcome
protective -X- _ I-Outcome
effects -X- _ I-Outcome
in -X- _ I-Outcome
EAE -X- _ I-Outcome
spinal -X- _ I-Outcome
cords -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
decreased -X- _ I-Outcome
demyelination. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Results -X- _ O
demonstrate -X- _ O
that -X- _ O
SIRT1 -X- _ B-Outcome
activating -X- _ I-Outcome
compounds -X- _ I-Outcome
prevent -X- _ I-Outcome
neuronal -X- _ I-Outcome
loss -X- _ I-Outcome
in -X- _ I-Outcome
viral-induced -X- _ I-Outcome
demyelinating -X- _ I-Outcome
disease -X- _ I-Outcome
similar -X- _ I-Outcome
to -X- _ I-Outcome
their -X- _ I-Outcome
effects -X- _ I-Outcome
in -X- _ I-Outcome
autoimmune-mediated -X- _ I-Outcome
disease. -X- _ I-Outcome
One -X- _ O
mechanism -X- _ O
of -X- _ O
this -X- _ O
neuroprotective -X- _ O
effect -X- _ O
involves -X- _ O
increasing -X- _ O
mitochondrial -X- _ O
biogenesis -X- _ O
with -X- _ O
reduction -X- _ O
of -X- _ O
oxidative -X- _ O
stress. -X- _ O
SIRT1 -X- _ O
activators -X- _ O
represent -X- _ O
a -X- _ O
potential -X- _ O
neuroprotective -X- _ O
therapy -X- _ O
for -X- _ O
MS. -X- _ O
Understanding -X- _ O
common -X- _ O
mechanisms -X- _ O
of -X- _ O
these -X- _ O
effects -X- _ O
in -X- _ O
distinct -X- _ O
disease -X- _ O
models -X- _ O
will -X- _ O
help -X- _ O
identify -X- _ O
targets -X- _ O
for -X- _ O
more -X- _ O
specific -X- _ O
therapies -X- _ O
. -X- _ O

